Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Shares of pharmaceutical giant Eli Lilly (NYSE:LLY) edged down 1.2% in premarket trading following announcements from ...

Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate activity to look forward to this week, which ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

Novo Nordisk is under investor pressure for transparency regarding their obesity drug CagriSema, after trial results disappointed. Patients report weight loss but side effects like nausea. Investors ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...